Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semaglutide attenuates neuroinflammation in male mice.

Nature communications·2026
Same author

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Diabetes, obesity & metabolism·2026
Same author

Correction: Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer's disease.

Alzheimer's research & therapy·2026
Same author

Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative review.

Contemporary oncology (Poznan, Poland)·2026
Same author

Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE).

Diabetes, obesity & metabolism·2026
Same author

Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden.

PharmacoEconomics·2026
Same journal

More Publications Needed on Cognitively Impaired-Not MCI: Call for Papers.

Alzheimer disease and associated disorders·2026
Same journal

CHMP2B p.Ala30Ser Variant in Biomarker-Confirmed Early-Onset Alzheimer Disease: A Potential Endolysosomal Disease Modifier.

Alzheimer disease and associated disorders·2026
Same journal

Early Gut Microbiome Alterations in Mild Cognitive Impairment Reflect Changes in Alzheimer Disease.

Alzheimer disease and associated disorders·2026
Same journal

Improvements in Cogstate Test Performance Depend on Number and Frequency of Prior Tests: Evidence from a Randomized Follow-Up Design.

Alzheimer disease and associated disorders·2026
Same journal

Identification of Functional lncRNAs in Alzheimer Disease by Integrative Analysis of lncRNA-mRNA Network Based on Competing Endogenous RNA Mechanism.

Alzheimer disease and associated disorders·2026
Same journal

Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical Trial.

Alzheimer disease and associated disorders·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory
08:08

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory

Published on: June 18, 2014

27.1K

Rescreening on RBANS Delayed Memory Index? Forget About It!

Marwan N Sabbagh1, Wojciech Michalak2, Charlotte Thim Hansen3

  • 1Department of Neurology, Barrow Neurological Institute, Phoenix, AZ.

Alzheimer Disease and Associated Disorders
|January 26, 2024
PubMed
Summary
This summary is machine-generated.

Rescreening Alzheimer's patients with initial low scores on the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) offers limited value. Most patients did not show significant cognitive decline or meet criteria for further assessment.

More Related Videos

A Dual Task Procedure Combined with Rapid Serial Visual Presentation to Test Attentional Blink for Nontargets
08:45

A Dual Task Procedure Combined with Rapid Serial Visual Presentation to Test Attentional Blink for Nontargets

Published on: December 5, 2014

9.2K
Using Rapid Serial Visual Presentation to Measure Set-Specific Capture, a Consequence of Distraction While Multitasking
05:58

Using Rapid Serial Visual Presentation to Measure Set-Specific Capture, a Consequence of Distraction While Multitasking

Published on: August 29, 2018

8.9K

Related Experiment Videos

Last Updated: Jul 4, 2025

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory
08:08

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory

Published on: June 18, 2014

27.1K
A Dual Task Procedure Combined with Rapid Serial Visual Presentation to Test Attentional Blink for Nontargets
08:45

A Dual Task Procedure Combined with Rapid Serial Visual Presentation to Test Attentional Blink for Nontargets

Published on: December 5, 2014

9.2K
Using Rapid Serial Visual Presentation to Measure Set-Specific Capture, a Consequence of Distraction While Multitasking
05:58

Using Rapid Serial Visual Presentation to Measure Set-Specific Capture, a Consequence of Distraction While Multitasking

Published on: August 29, 2018

8.9K

Area of Science:

  • Neuroscience
  • Gerontology
  • Clinical Psychology

Background:

  • Alzheimer's disease (AD) diagnosis relies on cognitive assessments.
  • The Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) is a key cognitive measure.
  • The utility of rescreening patients with borderline RBANS DMI scores is not well-established.

Purpose of the Study:

  • To evaluate the clinical value of rescreening patients with Alzheimer's disease who initially do not meet the inclusion criteria for the RBANS DMI.
  • To determine if initial RBANS DMI scores predict future cognitive decline or biomarker positivity.

Main Methods:

  • Analysis of data from the European Prevention of Alzheimer's Dementia database.
  • Inclusion of participants aged 50-85 without dementia, with Mini-Mental State Examination score ≥22, and baseline amyloid status.
  • Utilizing mixed-effects models for repeated measures and logistic regressions to analyze RBANS DMI score changes and progression.

Main Results:

  • Significant variability observed in RBANS DMI score changes over time.
  • Approximately 15% of participants with baseline RBANS DMI scores between 86-95 progressed to ≤85 at 6 months.
  • Of those progressing, 8% also met criteria for a Clinical Dementia Rating global score ≥0.5, and 5% were amyloid positive.

Conclusions:

  • Rescreening patients based solely on initial RBANS DMI scores has limited diagnostic or prognostic value.
  • The findings suggest that current rescreening protocols for Alzheimer's disease may not be optimized for patients with borderline initial cognitive test results.